Fritextsökning
Innehållstyper
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at app...
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
Next generation sequencer in an accessible format
The GS Junior System is a new benchtop-sized next generation sequencing platform.
-
Clinical trials in large scale to Stockholm
Karolinska Trial Alliance, KTA, will open a medical clinical for clinical trials in Phases II-IV. The clinic will be able to accommodate up to 150 patients per ...
-
Meda gets access to Asia
The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.
-
Negativa resultat i ny covidstudie med malariamedel
Ett malariamedel som prövas mot covid-19 gav inte effekt, enligt de första resultaten från en stor placebokontrollerad studie. Samtidigt hissar tidskriften Lanc...
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
Ola Weiland: ”Det är sällan man lyckas med en sån bedrift”
”Alla tre var viktiga och jag tycker det var rätt beslut”, säger Ola Weiland, senior professor i infektionssjukdomar vid Karolinska institutet, om valet av pris...
-
Fewer visitors but satisfied exhibitors
Biotech Forum Scanlab attracted fewer visitors than in 2008. Exhibition manager Bo Rasmussen is content, claiming that the exhibitors are very satisfied.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
Will the industry follow the economic revival?
Welcome to the eleventh Biotech Forum + Scanlab Fair!
-
Cancer cells cheat suicide call
Cancer cells cheat death by reversing a process which causes normal cells to commit suicide at the end of their natural life, researchers from the University of...
-
Danish biorefinery can save US billions
The Danish Inbicon biorefinery process could save the US billions on foreign oil, the organization states.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Changeable proteins cause nerve disease
An incorrectly folded protein is one of the reasons behind the nerve disease ALS, according to new research. But the protein does not have structural errors all...
-
Bio-Linux goes global
Recently the NEBC Bio-Linux Version 5.0 was released, a one-stop shop for bioinformatics tools in a Linux context.
-
A platform for dialogue
As a step towards connecting the life science industry in Denmark, Biologue was founded three years ago with 10 member companies. Today, the network has 40 memb...
-
Gabor Fischer, Distribution Sales Manager Europe, Ismatec
Why are you going to Scanlab+Biotech Forum?
-
Per Norstedt, Regional Manager, AH Diagnostics
Why are you going to Scanlab+Biotech Forum?
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study...
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.